
    
      This is an open-label single arm multi-center phase II study to assess the efficacy and
      safety of Fruquintinib in high risk patients with advanced NSCLC who is > 75 years, or ECOG
      PS = 2, or without systemic chemotherapy, or with at least three lines systemic
      chemotherapies.

      After checking eligibility criteria, subjects will take Fruquintinib as below: 4 mg once
      daily in the Cycle 1, administration for 3 weeks followed by 1 week break. 5mg once daily in
      followed cycles, administration for 3 weeks followed by 1 week break.

      Primary Efficacy Endpoint:

      Disease Control Rate (DCR) (According to RECIST Version 1.1). Safety and tolerance will be
      evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by
      severity in accordance with the National Cancer Institute (NCI) Common Terminology Criteria
      for Adverse Events (CTCAE) Version 4.0.

      Secondary Efficacy Endpoints:

      Objective Response Rate (ORR), Duration of Response (DOR), Progression free survival (PFS),
      Overall Survival (OS) and Quality of Life (QoL).
    
  